Nerdio Manager for Enterprise 7.0 Launches to Enhance Windows 365 and Cloud Desktop Management
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Nerdio, the automated End-User Computing…
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
- Full data from the Phase 3 TRuE-PN1 study, presented today in…
Frost & Sullivan Honors Forcepoint with the 2024 Global Company of the Year Award for Enabling “Data Security Everywhere”
Forcepoint is recognized for delivering a full lifecycle approach to data protection…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
PureTechs Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately…
Indusface Sets a New Standard with Industry-First 72-Hour API Compliance Capability on SwyftComply
VADODARA, India, Dec. 13, 2024 /PRNewswire/ -- Indusface, a leading application security SaaS…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…